Browse the evidence

Patients with severe obesity perceive obesity as a disease due to a lack of control and addiction-like mechanisms, yet simultaneously maintain a belief in personal responsibility and self-blame, creating a barrier to accepting the disease label fully.

Understand that accepting obesity as a disease is complex for many patients. While biological factors like genetics and appetite dysregulation play a huge role, many patients still feel personal responsibility. This internal conflict can hinder treatment. Healthcare providers should address this shame and the 'addiction' narrative to help patients accept medical interventions without feeling they are failing morally.

Continuous Positive Airway Pressure (CPAP) therapy has mixed and often limited effects on improving glycemic control (A1c, fasting glucose) and liver fat content in patients with OSA, T2DM, and MASLD, despite reducing sympathetic activity.

CPAP is essential for treating OSA and improving blood pressure, but it may not significantly lower blood sugar or liver fat on its own. If you have diabetes or fatty liver, focus on weight loss and medications, as CPAP alone may not reverse these conditions.

Intensive lifestyle intervention (ILI) involving weight loss and increased physical activity does not reduce the rate of major cardiovascular events in adults with type 2 diabetes and a history of cardiovascular disease, and may be associated with a higher incidence of nonfatal myocardial infarction compared to diabetes support and education.

If you have type 2 diabetes and a history of heart disease, intensive lifestyle changes focusing on heavy weight loss and high-volume exercise may not protect your heart and could potentially increase the risk of a non-fatal heart attack compared to standard education. Consult your doctor before starting intense exercise programs to ensure they are safe for your specific cardiac condition.

Generic public health messaging encouraging adults to 'eat less' or reduce caloric intake is ineffective and potentially harmful because it fails to provide actionable strategies, ignores complex social and environmental barriers, and can trigger negative psychological outcomes in vulnerable populations.

Stop telling people to 'eat less' or count calories, as this induces fear and confusion. Instead, provide specific, actionable instructions on how to increase nutrient-dense foods (like vegetables) to naturally crowd out calorie-dense options. Use trusted sources like healthcare providers to deliver these clear, behavior-based messages.

Calorie reduction messaging is counterproductive and potentially harmful for individuals with food insecurity or eating disorders, as it can reinforce distorted logic, rationalize harmful behaviors, or ignore survival priorities.

Do not use generic calorie reduction campaigns for food-insecure communities or individuals with eating disorders. For food-insecure groups, focus on access and quality, not restriction. For those with eating disorders, such messages can be dangerous and should be excluded or carefully managed by mental health professionals.

College students overwhelmingly perceive no-fat food preparations as healthier than those containing unsaturated or saturated fats, despite nutritional guidelines recommending unsaturated fats.

Stop avoiding fat. Choose foods with unsaturated fats (like olive oil, nuts, avocados) over no-fat options. The type of fat matters more for your health than simply removing fat from your diet.

Integrating structured intake tools (like the Obesity Brief HPI) into electronic medical records can increase the identification and prioritization of weight management visits, although adoption was zero in this baseline period.

Health systems are starting to use digital tools to make weight management easier. If your clinic uses these tools, expect a questionnaire before your visit. This is designed to help your doctor understand your history better, not to burden you.

Physical activity time and variability are not significantly associated with glycemic variability indices (MAGE, CONGA, MODD) in overweight or obese adults.

Do not rely on exercise alone to stop blood sugar spikes or swings if you are overweight. While exercise helps lower your average blood sugar, this study suggests it may not reduce the magnitude of glucose fluctuations. Focus on total movement time rather than expecting it to smooth out glucose curves.

There is no significant association between competitor characteristics (age, sex, drug status, level) and the use of carbohydrate-based peaking strategies or the length of the peaking strategy.

Do not assume your carbohydrate strategy must change based on your sex, age, or drug status. The study found no link between these factors and CHO strategy choice. However, be aware that the *range* of carbohydrate intake (high vs low days) during peak week is significantly influenced by sex.

GLP-1RAs may pose theoretical risks for individuals with restrictive eating disorders (e.g., Anorexia Nervosa) or high perfectionism, as appetite suppression can mask or reinforce rigid control and compensatory behaviors.

If you have a history of restrictive eating disorders or high perfectionism, GLP-1RAs require careful monitoring. The medication's ability to suppress appetite might mask or worsen restrictive behaviors, so prescribers should screen for these risks and watch for red flags like rapid weight loss or dizziness.

Pharmacotherapy may reduce bariatric surgical volume, particularly among patients with BMI 30-40, by providing a less invasive alternative.

If you have a BMI between 30 and 40, you now have a highly effective non-surgical option that may prevent the need for surgery. This is changing how doctors treat obesity.

Young adult males aiming to improve strength or develop muscle hypertrophy do not consistently follow current strength and conditioning recommendations, indicating a gap between guidelines and actual training practices.

If you are a young man trying to build muscle or strength, check if your current routine matches official guidelines (frequency, volume, intensity). If you are unsure, consult a certified strength and conditioning specialist to align your training with evidence-based standards rather than guessing.

Current US pharmacy school curricula provide insufficient education on obesity management and anti-obesity medications (AOMs), resulting in pharmacists being poorly prepared to counsel patients on pharmacotherapy options.

Pharmacists should recognize that current training may be insufficient for managing obesity pharmacotherapy. Seek out continuing education, such as the Obesity Medicine Association's proficiency badge or ASHP certificates, to bridge the gap in knowledge regarding AOMs and obesity management.

Automated dietary monitoring using social media data (text and images) is technically feasible and usable, but current accuracy levels (approx. 51% for fusion models) are insufficient for precise clinical nutrient tracking without manual verification.

Social media-based dietary apps can help you track food by reading your posts, but they are not yet accurate enough to rely on for precise calorie or nutrient counting. Use them as a rough guide or habit-builder, but verify specific nutritional needs manually or with a professional.

Social Determinants of Health (SDoH), including socioeconomic status, neighborhood environment, and food access, are strongly associated with obesity prevalence and weight regain, independent of individual clinical factors.

Your environment matters. If you live in an area with limited access to healthy food or safe places to exercise, maintaining weight loss is significantly harder. Recognizing these external barriers can help you seek community resources or advocate for policy changes that support your health goals.

Self-managed lifestyle interventions (diet and exercise) are the primary initial weight loss strategy in China, but they result in low compliance and modest efficacy, leading to a high unmet need for anti-obesity medications (AOMs).

If you are in China and trying to lose weight, know that self-managed diet and exercise are the standard first steps, but they often fail due to low compliance. If lifestyle changes aren't working, it is not your fault; the current options have limitations. Discuss anti-obesity medications (AOMs) with your doctor, as new options are becoming available and are desired by both patients and physicians for better efficacy and safety.

Time-restricted eating (TRE) with a duration of less than 8 hours per day is associated with an increased risk of cardiovascular mortality.

Be cautious with extreme time-restricted eating. While moderate fasting windows (12-16 hours) may improve insulin sensitivity, restricting your eating to less than 8 hours a day has been linked to higher cardiovascular mortality in large population studies. Stick to moderate approaches.

Precision nutrition and individualized interventions may not be sufficient to address obesity at a population level without addressing broader social, economic, and environmental determinants.

When seeking to improve health, look beyond individual diet plans. Advocate for and support policies that make healthy food affordable and accessible, and address social determinants like income and housing, as these are critical for long-term success.

Unsupervised resistance training in men with >3 years of experience fails to produce significant changes in fat-free mass or fat mass over 15 months.

If you have been lifting seriously for over three years and aren't seeing changes in muscle or fat despite training 3-5 times a week, your current self-directed approach has likely plateaued. You likely need professional guidance to systematically adjust training variables and nutrition, as self-regulation alone is insufficient for continued progress in advanced lifters.

Inpatient initiation of obesity-targeted therapies (GLP-1 agonists, referrals) for Class 2 and 3 obesity is currently rare and represents a significant gap in care, despite high recognition rates.

If you have Class 2 or 3 obesity, your hospitalization is a critical window for treatment. Doctors often recognize the diagnosis but fail to prescribe medication or refer you to weight management clinics. You must proactively ask for a referral to a weight management clinic or a prescription for weight management medication (like GLP-1 agonists) before discharge to ensure continuity of care.

Prior use of anti-obesity medications (AOMs) does not alter patient motivations for seeking bariatric surgery, as patients prioritize health and longevity regardless of prior pharmaceutical weight loss attempts.

If you have tried weight loss medications without success, do not assume your reasons for wanting surgery are different from others. Your desire for better health and longevity is the same as those who haven't used drugs. Surgery offers a different mechanical approach to weight loss that is not dependent on your prior response to medications.

MBS is associated with a higher risk of divorce or separation compared to the general population, particularly within the first five years post-surgery.

Be aware that your relationship dynamics may change significantly after surgery. While many relationships improve, there is a statistically higher risk of separation. Proactive communication and counseling can help navigate these changes.

Online marketing of GLP-1 receptor agonists as 'weight loss injections' creates unrealistic expectations and encourages off-label, non-medical use, posing significant public health risks.

Be skeptical of online content that promotes GLP-1 injections as 'weight loss injections' without mentioning medical indications, side effects, or the need for a prescription. These are serious medications for obesity management, not cosmetic shortcuts. Consult a healthcare provider to determine if you are a suitable candidate and to understand the risks and benefits.

Current economic models often undervalue incretin therapies by excluding downstream benefits (e.g., reduced MACE, sleep apnea, osteoarthritis), leading to high ICERs that may exceed willingness-to-pay thresholds without price reductions.

For payers, these drugs are expensive. However, if you account for long-term health savings (fewer heart attacks, surgeries), they can be cost-effective, especially if the price is lowered or targeted at high-risk patients.